LLY · November 22, 2026 · Free preview
Eli Lilly discounted cash flow valuation
Can Lilly grow obesity and diabetes sales fast enough to pay for new capacity and replenish its drug portfolio?
Lilly raised its 2026 revenue outlook to $91–$92 billion. The September quarter included $4.18 billion of acquired in-process research and development expense. Company filing or announcement
Read the full valuation
See fair value against the November 20 close, the operating margin that price implies, three operating scenarios and the effect of changing the discount rate or long-run growth.